Skip to main content
Article thumbnail
Location of Repository

Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy: results from the AMADEO study

By Prasad Bichu, Ravi Nistala, Asma Khan, James R Sowers and Adam Whaley-Connell


Diabetic kidney disease is characterized by persistent albuminuria (>300 mg/dl or >200 μg/min) that is confirmed on at least 2 occasions 3 to 6 months apart, with a progressive decline in the glomerular filtration rate (GFR), elevated arterial blood pressure, and an increased risk for cardiovascular morbidity and mortality. Diabetic kidney disease is the leading cause of end stage renal disease (ESRD) prompting investigators to evaluate mechanisms by which to slow disease progression. One such mechanism is to block the activity of angiotensin II at the receptor site and agents that follow this mechanism are referred to as angiotensin receptor blockers (ARB). There is sufficient clinical evidence to support that ARB have protective effects on kidney function in patients with diabetes and hypertension. However, in the past decade there have been few investigations comparing individual ARBs on renal outcomes. Telmisartan, a lipophilic ARB with a long half-life, has been hypothesized to have a greater anti-proteinuric effect when compared to the shorter acting losartan. Therefore, the A comparison of telMisartan versus losArtan in hypertensive type 2 DiabEtic patients with Overt nephropathy (AMADEO) trial sought to investigate renal and cardiovascular endpoints. In this review, we discuss the pathophysiology of diabetic kidney disease and implications of the AMADEO trial in the context of current understanding from recent outcome trials

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2006). A review on telmisartan: a novel, long-acting angiotensin II-receptor. Cardiovasc Drug Rev.
  2. a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
  3. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.
  4. Aldosterone antagonism ameliorates proteinuria and nephrosclerosis independent of glomerular dynamics.
  5. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats.
  6. Angiotensin II type-1-receptor antagonists from the viewpoint of nephrology.
  7. (2008). Association. Standards of Medical Care in Diabetes. Diabetes Care.
  8. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy.
  9. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
  10. Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fl uid retention.
  11. (2007). Diabetes Fact Sheet.
  12. Diabetics Exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
  13. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.
  14. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria.
  15. (2007). Foundation, KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis.
  16. Identifi cation of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity.
  17. (2007). Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care.
  18. (2008). Investigational drugs for diabetic nephropathy. Expert Opin Investig Drugs.
  19. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
  20. (2004). Mechanisms of disease: local renin angiotensin aldosterone systems and the pathogenesis and treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med.
  21. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.
  22. Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity.
  23. Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes.
  24. (2008). Pathogenesis of the podocytopathy and proteinuria in diabetic glomerulopathy. Current Diabetes Reviews.
  25. Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist,
  26. (2007). Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension.
  27. (2005). PPAR gamma agonists exert antifi brotic effects in renal tubular cells exposed to high glucose. Am J Physiol Renal Physiol.
  28. Prevention and treatment of diabetic renal disease
  29. (2007). Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care.
  30. (2008). Prospects for renovascular protection by more aggressive renin-angiotensin system control.
  31. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition.
  32. ramipril, or both in patients at high risk for vascular events.
  33. (2008). Redox control of renal function and hypertension. Antioxid Redox Signal.
  34. Reduction of proteinuria with angiotensin receptor blockers.
  35. RENAAL Study Investigators. Losartan in patients with type 2 diabetes and proteinuria: Observations from the RENAAL Study.
  36. Renal and vascular mechanisms of thiazolidinedione-induced fl uid retention.
  37. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial.
  38. Role of mesangial expansion in the pathogenesis of diabetic nephropathy.
  39. Safety issues and prospects for future generations of PPAR modulators.
  40. (2007). Selective modulators of PPAR-γ activity: molecular aspects related to obesity and side-effects. PPAR Res.
  41. Telmisartan has the strongest binding affi nity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers.
  42. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy.
  43. (2000). The Irbesartan Type II Diabetic Nephropathy Trial. Nephrol Dial Transplant.
  44. (2008). The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab.
  45. The Telmisartan Renoprotective Study from Incipient Nephropathy to Overt Nephropathy – Rationale, Study Design, Treatment Plan and
  46. Thiazolidinediones expand body fl uid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption.
  47. (2008). VIVALDI investigators. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.